home

Teva, Allergan generics deal on track to close in June: Analyst

Commentsfiercepharma2016-04-26 13:13 Read   135

Relax, Teva and Allergan investors. The companies are on track to close their whopper knockoffs deal in the first half of June or so, one analyst says.

Novartis puts $14B Roche stake up for sale: Reports

Commentsfiercepharma2016-04-26 13:05 Read   140

Will Novartis sell its big stake in crosstown rival Roche?

Novartis CEO: The racehorse drug launch is over in the U.S.

Commentsfiercepharma2016-04-26 12:40 Read   161

Beware the U.S. drug launch. That’s the word from Novartis CEO Joe Jimenez, whose much-anticipated Entresto rollout started with a whimper rather than a bang stateside.

Germany planning to table pricing reforms 'by the summer'

Commentspmlive2016-04-26 11:15 Read   114

Germany is considering a shake-up of its pricing system for medicinal products, including discounts on drugs that cross a sales threshold.

Patient advocates descend on FDA panel as Sarepta squares off against regulators

Commentsfiercebiotech2016-04-26 09:20 Read   84

Hundreds of Duchenne muscular dystrophy activists descended on an FDA panel review of Sarepta's eteplirsen Monday morning, looking to exert the maximum amount of pressure possible to spur an endorsement from the experts.

WHO stays positive as dose of reality hits malaria vaccine hopes

Commentsfirst word2016-04-25 15:15 Read   86

The World Health organization (WHO) has ordered up to five pilot programmes to take place in sub-Saharan Africa to test GlaxoSmithKline's malaria vaccine Mosquirix, also known as RTS, S, and only if those prove successful will a wider go-ahead be given, reported the Financial Times.

FirstWord Lists: The 50 fastest growing pharmaceutical brands in 2015

CommentsFirstWord2016-04-25 14:47 Read   191

The 50 fastest growing pharmaceutical products (calculated by subtracting 2014 sales from 2015 sales) generated combined year-on-year growth of $41 billion in 2015.

Pharma and payers agree: It's time for more dialogue on drug pricing

Commentsfiercepharma2016-04-25 10:17 Read   78

When it comes to rising drug costs, payers and pharma rarely see eye-to-eye. But more back-and-forth conversation could go a long way in easing some of the tension, both sides are saying. And a little regulatory overhaul could help make this a possibility.

Industry welcomes India regulator notice on academic trials

Commentsfiercepharma2016-04-25 10:09 Read   86

A notice by the Drug Controller General of India (DCGI) has paved the way for a variety of much needed new clinical research by academics on already approved drugs, the Indian Society for Clinical Research (ISCR) said.

U.S. Suicide Rate Up 24 Percent Since 1999: CDC

CommentsDRUGS2016-04-25 09:28 Read   73

Suicide rates in the United States rose 24 percent between 1999 and 2014, with young girls and middle-aged men accounting for the largest increases, federal health officials reported Friday.

Sarepta soars after FDA questions revive advocates’ hope for Duchenne drug

Commentsfiercebiotech2016-04-25 08:58 Read   89

Friday afternoon, Sarepta’s path to a formal marketing decision from the FDA on its Duchenne muscular dystrophy drug eteplirsen took yet another bizarre twist.

Insurers, Drugmakers Want to Exchange Info on Specialty Drugs

Commentsmorningconsult2016-04-22 11:18 Read   92

There is a lot of disagreement about what to do about high drug costs. But in at least one case, frequent foes, insurers and drug companies, agree.